The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survey on management of metastatic hormone-refractory prostate cancer upon progression during or following first-line chemotherapy in five European countries.
Sebastien Auziere
Employment or Leadership Position - Sanofi (I)
Stock Ownership - Sanofi (I)
Research Funding - Sanofi (I)
Alain Flinois
No relevant relationships to disclose
Eliot Obi-Tabot
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Mathieu Rose
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Adam Parnaby
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi